Indian pharma companies secure 51 final ANDA approvals during Jan-March 2018
Indian companies have secured 51 final ANDA approvals from US FDA during the first quarter of January-March 2018, out of total 112 approvals. This worked out to 45 per cent of total approvals in the first quarter. During the same period last year, Indian companies had grabbed 55 final ANDA approvals out of 171 approved by US FDA. Further, Indian companies received 6 tentative approvals from aggregate 23 tentative approvals in the first quarter of Jan-March 2018. The overall approvals declined to 112 ANDAs from 171 ANDAs in the same quarter of last year and 23 tentative approvals as compared to 43 tentative approvals. Aurobindo Pharma has received the highest numbers of ANDA approvals among the Indian companies during the first quarter of 2018. It received 11 final ANDA approvals followed by Strides Shasun 6, Lupin 5, Cipla and Zydus Pharma 4 each, Dr Reddy's Laboratories, Hetero Labs and Taro Pharma 3 each. Macleods Pharma and Vivimed Global received 2 approval each. ...